|
US4933168A
(en)
*
|
1975-05-27 |
1990-06-12 |
Syntex Pharmaceuticals International Limited |
Stable, crystalline flunisolide
|
|
MX3864E
(es)
*
|
1975-05-27 |
1981-08-26 |
Syntex Corp |
Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
|
|
GB1571629A
(en)
*
|
1977-11-30 |
1980-07-16 |
Fisons Ltd |
Pharmaceutical compositions containing beclomethasone dipropionate
|
|
IT1121513B
(it)
*
|
1979-05-28 |
1986-04-02 |
Chiesi Farma Spa |
Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
|
|
EP0039369B1
(fr)
*
|
1980-05-02 |
1983-06-15 |
Schering Corporation |
Solvats d'esters de béclométhasone, procédé pour leur préparation et préparation d'une formulation
|
|
FI63672C
(fi)
*
|
1980-05-19 |
1983-08-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
|
|
KR890000664B1
(ko)
*
|
1981-10-19 |
1989-03-22 |
바리 안소니 뉴우샘 |
미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
|
|
GB8432063D0
(en)
*
|
1984-12-19 |
1985-01-30 |
Riker Laboratories Inc |
Physically modified steroids
|
|
US5962490A
(en)
*
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5562608A
(en)
*
|
1989-08-28 |
1996-10-08 |
Biopulmonics, Inc. |
Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
|
|
US5736509A
(en)
*
|
1990-12-14 |
1998-04-07 |
Texas Biotechnology Corporation |
Cyclic peptide surface feature mimics of endothelin
|
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
IL104068A
(en)
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
|
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
|
US5683676A
(en)
*
|
1991-12-12 |
1997-11-04 |
Glaxo Group Limited |
Canister containing aerosol formulations containing P134a and particulate medicaments
|
|
JP3026841B2
(ja)
|
1991-12-12 |
2000-03-27 |
グラクソ、グループ、リミテッド |
医 薬
|
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US5301664A
(en)
*
|
1992-03-06 |
1994-04-12 |
Sievers Robert E |
Methods and apparatus for drug delivery using supercritical solutions
|
|
CA2115065C
(fr)
*
|
1992-06-12 |
2000-10-03 |
Kiyoyuki Sakon |
Poudre particulaire ultrafine pour inhalation et methode de production
|
|
MX9304585A
(es)
|
1992-07-31 |
1994-03-31 |
Glaxo Group Ltd |
Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
|
|
AU6554194A
(en)
*
|
1993-04-01 |
1994-10-24 |
Amgen, Inc. |
Method for preparing drugs to treat dermal disorders
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6030991A
(en)
*
|
1993-05-20 |
2000-02-29 |
Texas Biotechnology Corp. |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
|
AU693590B2
(en)
*
|
1994-08-09 |
1998-07-02 |
Schering Corporation |
Process for preparing beclomethasone dipropionate freon (R) clathrate
|
|
US5980949A
(en)
*
|
1994-10-03 |
1999-11-09 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5983956A
(en)
*
|
1994-10-03 |
1999-11-16 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US6017887A
(en)
*
|
1995-01-06 |
2000-01-25 |
Sibia Neurosciences, Inc. |
Peptide, peptide analog and amino acid analog protease inhibitors
|
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
|
US5646130A
(en)
*
|
1995-06-30 |
1997-07-08 |
Ocean University Of Oingdao |
Low molecular weight sulfated polysaccharides and uses thereof
|
|
US5977117A
(en)
*
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
|
US5700487A
(en)
*
|
1996-03-04 |
1997-12-23 |
The Ohio State University |
Treatment of pulmonary inflammation
|
|
US5958905A
(en)
|
1996-03-26 |
1999-09-28 |
Texas Biotechnology Corporation |
Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
|
|
US5804585A
(en)
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
|
EP0935415B1
(fr)
*
|
1996-05-01 |
2006-11-22 |
Imarx Pharmaceutical Corp. |
Procedes d'apport d'acides nucleiques dans une cellule in vitro
|
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
|
SE9603725D0
(sv)
*
|
1996-10-11 |
1996-10-11 |
Astra Ab |
New teatment
|
|
US6380222B2
(en)
*
|
1996-10-11 |
2002-04-30 |
Astrazeneca Ab |
Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
|
|
AU741076B2
(en)
|
1996-12-12 |
2001-11-22 |
Prolume, Ltd. |
Apparatus and method for detecting and identifying infectious agents
|
|
SE9700135D0
(sv)
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
SE9700133D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
PL197843B1
(pl)
|
1997-04-28 |
2008-05-30 |
Encysive Pharmaceuticals Inc |
Farmaceutycznie dopuszczalne sole metali alkalicznych ze związkami sulfonoamidowymi, środek farmaceutyczny, zastosowanie farmaceutycznie dopuszczalnych soli metali alkalicznych ze związkami sulfonoamidowymi, sposób wytwarzania liofilizowanego proszku i sposób wytwarzania farmaceutycznie dopuszczalnych soli metali alkalicznych ze związkami sulfonoamidowymi
|
|
US6342611B1
(en)
*
|
1997-10-10 |
2002-01-29 |
Cytovia, Inc. |
Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
AU2868099A
(en)
|
1998-02-13 |
1999-08-30 |
Selective Genetics, Inc. |
Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
|
|
EP1925320A3
(fr)
|
1998-03-27 |
2008-09-03 |
Prolume, Ltd. |
Luciférases, protéines fluorescentes, acides nucléiques codant pour les luciférases et protéines fluorescentes et leur utilisation pour le diagnostic, le criblage à haut rendement et articles nouveaux
|
|
US6248904B1
(en)
*
|
1998-07-21 |
2001-06-19 |
Cytovia, Inc. |
Fluorescence dyes and their applications for whole-cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
|
|
US6667299B1
(en)
*
|
2000-03-16 |
2003-12-23 |
Hollis-Eden Pharmaceuticals, Inc. |
Pharmaceutical compositions and treatment methods
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
AU1624801A
(en)
|
1999-11-19 |
2001-05-30 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists related applications
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
HUP0203935A3
(en)
|
1999-12-31 |
2006-02-28 |
Encysive Pharmaceuticals Inc H |
Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use
|
|
US7109315B2
(en)
|
2000-03-15 |
2006-09-19 |
Bruce J. Bryan |
Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
|
|
US6596262B2
(en)
|
2001-02-15 |
2003-07-22 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6544497B2
(en)
|
2001-02-15 |
2003-04-08 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6485707B2
(en)
|
2001-02-15 |
2002-11-26 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
|
US20030129203A1
(en)
*
|
2001-08-27 |
2003-07-10 |
Nautilus Biotech S.A. |
Mutant recombinant adeno-associated viruses
|
|
EP1446110A2
(fr)
*
|
2001-10-16 |
2004-08-18 |
Structural Bioinformatics Inc. |
Organosulfures inhibiteurs de tyrosine phosphatases
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
WO2003060078A2
(fr)
*
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Modulateurs heterocycliques de recepteurs nucleaires
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
ES2421511T3
(es)
|
2001-12-21 |
2013-09-03 |
X Ceptor Therapeutics Inc |
Moduladores de LXR
|
|
US20030199594A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Rasik Shah |
Helium propellant composition for use with aerosols
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
AU2003248747A1
(en)
|
2002-06-27 |
2004-01-19 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
|
EP1606291A2
(fr)
|
2002-07-02 |
2005-12-21 |
Health Research, Inc. |
Synthese efficace de pyropheophorbide a et ses derives
|
|
DE60332358D1
(de)
*
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
US20060020396A1
(en)
*
|
2002-09-09 |
2006-01-26 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US20050202438A1
(en)
*
|
2002-09-09 |
2005-09-15 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
JP4206382B2
(ja)
|
2002-11-19 |
2009-01-07 |
アキリオン ファーマシューティカルズ，インコーポレーテッド |
置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター
|
|
WO2004060260A2
(fr)
*
|
2002-12-18 |
2004-07-22 |
Glaxo Group Limited |
Systeme d'administration de medicament dote d'un embout buccal a event
|
|
JP4464395B2
(ja)
|
2003-03-05 |
2010-05-19 |
ヘイローザイム インコーポレイテッド |
可溶性ヒアルロニダーゼ糖タンパク質（ｓＨＡＳＥＧＰ）、その調製プロセス、使用およびそれを含む薬学的組成物
|
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7244739B2
(en)
*
|
2003-05-14 |
2007-07-17 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
|
CA2528438A1
(fr)
*
|
2003-06-03 |
2005-01-06 |
Novartis Ag |
Inhibiteurs de p-38
|
|
EP1911754B1
(fr)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de peptidase dipeptidyl
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(fr)
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
|
|
US8519158B2
(en)
*
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
EP1768968A1
(fr)
|
2004-05-20 |
2007-04-04 |
Foldrx Pharmaceuticals, Inc. |
Composes 2-(heteroaryl)benzoxazoles et derives, compositions et procedes servant a stabiliser la transthyretine et a inhiber le mauvais repliement de la transthyretine
|
|
EP1765332A2
(fr)
*
|
2004-06-17 |
2007-03-28 |
Cengent Therapeutics, Inc. |
Modulateurs a base d'azote trisubstitue de tyrosine phosphatases
|
|
EP1786421A2
(fr)
*
|
2004-07-09 |
2007-05-23 |
Cengent Therapeutics, Inc. |
Inhibiteurs de tyrosine phosphatases a heterocycle oxygene/azote
|
|
WO2006017295A2
(fr)
|
2004-07-12 |
2006-02-16 |
Idun Pharmaceuticals, Inc. |
Analogues de tetrapeptide
|
|
WO2006028970A1
(fr)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derives d'inhibiteurs de thiazole et de thiadiazole de tyrosine phosphatases
|
|
EP2433634A3
(fr)
|
2004-09-17 |
2012-07-18 |
The Whitehead Institute for Biomedical Research |
Composés, compositions et procédés d'inhibition de toxicité d'a-synucleine
|
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
|
WO2006068978A2
(fr)
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Inhibiteurs de dipeptidyle peptidase
|
|
ATE534652T1
(de)
|
2005-04-01 |
2011-12-15 |
Univ California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
|
KR20080019606A
(ko)
*
|
2005-05-04 |
2008-03-04 |
나우틸루스 바이오텍 |
변형된 인터페론-감마 폴리펩티드 및 변형된 인터페론-감마폴리펩티드를 사용하는 방법
|
|
BRPI0609191B8
(pt)
*
|
2005-06-17 |
2021-05-25 |
Ligand Pharm Inc |
métodos e compostos moduladores de receptor de androgênio
|
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
NZ595193A
(en)
|
2005-10-21 |
2013-09-27 |
Catalyst Biosciences Inc |
Modified Proteases That Inhibit Complement Activation
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
MX2008011633A
(es)
|
2006-03-13 |
2008-12-16 |
Activx Biosciences Inc |
Aminoquinolonas como inhibidores de gsk-3.
|
|
US20080038224A1
(en)
*
|
2006-03-28 |
2008-02-14 |
Thierry Guyon |
Modified interferon-beta (IFN-beta) polypeptides
|
|
BRPI0709699A2
(pt)
*
|
2006-03-29 |
2011-07-26 |
Foldrx Pharmaceuticals Inc |
inibiÇço da toxidez da alfa-sinucleina
|
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
|
EP2423307A1
(fr)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Polypeptides du facteur IV à coagulation modifiée et leur utilisation pour le traitement
|
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
|
DK2066662T3
(da)
|
2006-09-21 |
2013-01-07 |
Kyorin Seiyaku Kk |
Serinhydrolaseinhibitorer
|
|
JP2010505961A
(ja)
|
2006-10-09 |
2010-02-25 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
AU2007313961A1
(en)
|
2006-10-09 |
2008-05-08 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP2113500A1
(fr)
|
2006-10-31 |
2009-11-04 |
Takeda Pharmaceutical Company Limited |
Inhibitêur du kinàse MAPK/ERK
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
WO2009070164A1
(fr)
|
2007-11-28 |
2009-06-04 |
University Of Central Florida |
Amélioration de la vigueur par administration de dérivés de pyrimidine
|
|
JP2010510794A
(ja)
|
2006-11-28 |
2010-04-08 |
ハナル ファーマシューティカル カンパニー リミテッド |
修飾型エリスロポエチンポリペプチド及びこの治療用用途
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
KR20090086115A
(ko)
*
|
2006-12-22 |
2009-08-10 |
엔싸이시브 파마슈티칼즈 인코퍼레이티드 |
Ｃ３ａ 수용체의 조정제 및 이의 사용 방법
|
|
CA2677838C
(fr)
|
2007-02-11 |
2017-08-01 |
Map Pharmaceuticals, Inc. |
Procede d'administration therapeutique de dhe pour procurer un soulagement rapide de la migraine tout en minimisant le profil des effets secondaires
|
|
PT2144604E
(pt)
|
2007-02-28 |
2011-10-19 |
Conatus Pharmaceuticals Inc |
Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
|
|
KR101563018B1
(ko)
*
|
2007-09-11 |
2015-10-23 |
교린 세이야꾸 가부시키 가이샤 |
Ｇｓｋ-３ 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론
|
|
JP5373799B2
(ja)
|
2007-09-12 |
2013-12-18 |
杏林製薬株式会社 |
Ｇｓｋ−３阻害剤としてのスピロ環式アミノキノロン
|
|
MX2010003249A
(es)
|
2007-09-25 |
2010-11-09 |
Takeda Pharmaceutical |
Inhibidores de quinasas símil polo.
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
US8426587B2
(en)
*
|
2007-11-21 |
2013-04-23 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
|
|
US8354446B2
(en)
|
2007-12-21 |
2013-01-15 |
Ligand Pharmaceuticals Incorporated |
Selective androgen receptor modulators (SARMs) and uses thereof
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
EP2285402A2
(fr)
|
2008-04-14 |
2011-02-23 |
Halozyme, Inc. |
Hyaluronidases modifiées et utilisations pour traiter des maladies et des pathologies associées à l'acide hyaluronique
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
US20110178070A1
(en)
|
2008-06-24 |
2011-07-21 |
Takeda Pharmaceutical Company Limited |
PI3K/mTOR INHIBITORS
|
|
EP2318035B1
(fr)
|
2008-07-01 |
2019-06-12 |
Curemark, Llc |
Procédés et compositions pour le traitement de symptômes de troubles de santé neurologiques et mentaux
|
|
DK3037529T3
(da)
|
2008-12-09 |
2019-05-20 |
Halozyme Inc |
Udvidede opløselige ph20-polypeptider og anvendelse deraf
|
|
KR20170005191A
(ko)
|
2009-01-06 |
2017-01-11 |
큐어론 엘엘씨 |
이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
|
|
ES2882518T3
(es)
|
2009-01-06 |
2021-12-02 |
Galenagen Llc |
Composición que comprende proteasa, amilasa y lipasa
|
|
US20110229451A2
(en)
*
|
2009-03-06 |
2011-09-22 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloproteases and uses thereof
|
|
AU2010221990B2
(en)
*
|
2009-03-11 |
2015-06-04 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as GSK-3 inhibitors
|
|
EP2415767B1
(fr)
|
2009-03-27 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la poly(ADP-ribose)polymérase (PARP)
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP2459561A1
(fr)
|
2009-07-30 |
2012-06-06 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la poly (adp-ribose) polymérase (parp)
|
|
WO2011041293A1
(fr)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
|
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
|
US8648073B2
(en)
*
|
2009-12-30 |
2014-02-11 |
Fochon Pharma, Inc. |
Certain dipeptidyl peptidase inhibitors
|
|
PL2531501T3
(pl)
|
2010-02-03 |
2014-05-30 |
Takeda Pharmaceuticals Co |
Inhibitory kinazy 1 regulującej sygnał apoptotyczny
|
|
EP2585455B1
(fr)
|
2010-06-24 |
2019-08-07 |
The Regents of the University of California |
Composés et leurs utilisations dans la modulation des niveaux de différentes alloformes du peptide amyloïde bêta
|
|
ES2804223T3
(es)
|
2011-04-21 |
2021-02-04 |
Curemark Llc |
Compuestos para el tratamiento de Trastornos Neuropsiquiátricos
|
|
KR20140042868A
(ko)
|
2011-06-23 |
2014-04-07 |
맵 파마슈티컬스, 인코포레이티드 |
신규한 플루오로에르골린 유사체
|
|
WO2013037482A1
(fr)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
|
|
SG10201509139QA
(en)
|
2011-12-19 |
2015-12-30 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
|
SG11201403433PA
(en)
|
2011-12-21 |
2014-07-30 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
|
IL298330A
(en)
|
2011-12-30 |
2023-01-01 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
|
EP3971178A1
(fr)
|
2012-03-07 |
2022-03-23 |
The McLean Hospital Corporation |
Dérivés d'aminoquinoléine et leurs utilisations
|
|
EA031986B1
(ru)
|
2012-04-04 |
2019-03-29 |
Галозим, Инк. |
Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
|
|
ES2668300T3
(es)
|
2012-05-02 |
2018-05-17 |
Boehringer Ingelheim International Gmbh |
Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
WO2013187965A1
(fr)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Dérivés de pyrazole en tant qu'inhibiteurs de stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
|
US20150196625A9
(en)
|
2013-01-07 |
2015-07-16 |
Rudolph D. Paladini |
Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
|
|
WO2014130908A1
(fr)
|
2013-02-22 |
2014-08-28 |
University Of Southern California |
Méthodes de traitement de maladies et de troubles ophtalmiques
|
|
EP2968296B1
(fr)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Modulateurs de gamma-secrétase
|
|
CA2911376C
(fr)
|
2013-03-15 |
2021-03-30 |
University Of Southern California |
Derives de phenyle (sulfonylcarbamate) et compositions pharmaceutiques de ceux-ci pour le traitement de maladies liees a l'angiotensine
|
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
EP3613418A1
(fr)
|
2014-01-17 |
2020-02-26 |
Ligand Pharmaceuticals, Inc. |
Procédés et compositions de modulation des niveaux d'hormones
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
RU2016148364A
(ru)
|
2014-05-12 |
2018-06-13 |
Конатус Фармасьютикалз, Инк. |
Лечение осложнений хронического заболевания печени
|
|
KR102433464B1
(ko)
|
2014-05-28 |
2022-08-17 |
아게누스 인코포레이티드 |
항-gitr 항체 및 이의 사용 방법
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
|
EP3209658A1
(fr)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Dérivés de diterpénoïdes et leurs procédés d'utilisation
|
|
US10472346B2
(en)
|
2014-10-31 |
2019-11-12 |
The General Hospital Corporation |
Potent gamma-secretase modulators
|
|
CN114230664A
(zh)
|
2014-12-11 |
2022-03-25 |
皮埃尔法布雷医药公司 |
抗c10orf54抗体及其用途
|
|
EP3789039A1
(fr)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anticorps agonistes anti-mertk et leurs utilisations
|
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
|
AU2016209492B2
(en)
|
2015-01-20 |
2020-10-22 |
Xoc Pharmaceuticals, Inc |
Ergoline compounds and uses thereof
|
|
DE112016001013T5
(de)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
Antikörper, verwendungen und verfahren
|
|
EP3289104B1
(fr)
|
2015-04-29 |
2020-11-04 |
New York University |
Procédé pour le traitement de gliomes de haut grade
|
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
SG10202101740QA
(en)
|
2015-08-17 |
2021-04-29 |
Kura Oncology Inc |
Methods of treating cancer patients with farnesyl transferase inhibitors
|
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
|
WO2017079566A1
(fr)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
CN108697663A
(zh)
|
2015-12-31 |
2018-10-23 |
科内图斯医药公司 |
在肝病治疗中使用胱天蛋白酶抑制剂的方法
|
|
CN108712904B
(zh)
|
2016-01-08 |
2022-08-02 |
细胞基因公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
|
|
HUE051231T2
(hu)
|
2016-01-08 |
2021-03-01 |
Celgene Corp |
Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai
|
|
KR20180095094A
(ko)
|
2016-01-08 |
2018-08-24 |
셀진 코포레이션 |
암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
|
|
WO2017151836A1
(fr)
|
2016-03-04 |
2017-09-08 |
East Carolina University |
Prostaglandine-éthanolamides de série j utilisés comme nouveaux agents thérapeutiques pour des troubles de la peau et/ou bucco-dentaires
|
|
EP3426301A4
(fr)
|
2016-03-08 |
2019-11-06 |
Los Gatos Pharmaceuticals, Inc. |
Nanoparticules composites et utilisations desdites nanoparticules
|
|
WO2017156183A1
(fr)
|
2016-03-08 |
2017-09-14 |
Los Gatos Pharmaceuticals, Inc. |
Dérivés de camptothécine et leurs utilisations
|
|
WO2017180794A1
(fr)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
|
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
DK3454904T3
(da)
|
2016-05-13 |
2023-02-06 |
Pasteur Institut |
Inhibering af beta-2-nikotiniske acetylcholinreceptorer til at behandle patologi ved Alzheimers sygdom
|
|
SG10201912563XA
(en)
|
2016-05-27 |
2020-02-27 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
|
JP2019525772A
(ja)
|
2016-07-08 |
2019-09-12 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ａｐｏｃ３抗体およびその使用方法
|
|
WO2018035281A1
(fr)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Voie nord-sud pour la synthèse de bactériochlorines
|
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
WO2018083248A1
(fr)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
|
|
JP2019534290A
(ja)
|
2016-11-03 |
2019-11-28 |
クラ オンコロジー， インコーポレイテッド |
癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
|
|
KR102431830B1
(ko)
|
2016-11-07 |
2022-08-16 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
|
WO2018089692A1
(fr)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Dérivés d'eckol, procédés de synthèse et utilisations associées
|
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
AU2017373945A1
(en)
|
2016-12-07 |
2019-06-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
MX2019006340A
(es)
|
2016-12-07 |
2019-11-07 |
Agenus Inc |
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
|
|
EP3432883B1
(fr)
|
2017-02-21 |
2021-07-28 |
Kura Oncology, Inc. |
Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
WO2018193427A1
(fr)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
|
MA50957A
(fr)
|
2017-05-01 |
2020-10-14 |
Agenus Inc |
Anticorps anti-tigit et leurs méthodes d'utilisation
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
AU2018275873A1
(en)
|
2017-06-01 |
2019-12-19 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
US10781435B2
(en)
|
2017-06-22 |
2020-09-22 |
Catalyst Biosciences, Inc. |
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
|
|
US10323289B2
(en)
|
2017-06-26 |
2019-06-18 |
Institut Pasteur |
Treatments to eliminate HIV reservoirs and reduce viral load
|
|
KR20220031738A
(ko)
|
2017-06-27 |
2022-03-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
|
CN111315774B
(zh)
|
2017-06-27 |
2023-12-22 |
纽洛可科学有限公司 |
抗fam19a5抗体及其用途
|
|
EP3645039A4
(fr)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
|
|
US11746149B2
(en)
|
2017-06-27 |
2023-09-05 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
|
|
EP3652318A1
(fr)
|
2017-07-11 |
2020-05-20 |
Actym Therapeutics, Inc. |
Souches bactériennes immunostimulatrices modifiées et utilisations
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
MY200746A
(en)
|
2017-08-07 |
2024-01-13 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019046556A1
(fr)
|
2017-09-01 |
2019-03-07 |
East Carolina University |
Composés, compositions, kits et procédés pour activer des cellules immunitaires et/ou une réponse de système immunitaire
|
|
MA50516A
(fr)
|
2017-10-31 |
2020-09-09 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs procédés d'utilisation
|
|
WO2019099353A1
(fr)
|
2017-11-15 |
2019-05-23 |
California State University Northridge |
Compositions et procédés pour le traitement et la prévention du cancer
|
|
WO2019113269A1
(fr)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
|
KR20240060864A
(ko)
|
2018-04-24 |
2024-05-08 |
주식회사 뉴라클사이언스 |
신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
|
|
CN112119091A
(zh)
|
2018-05-10 |
2020-12-22 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
WO2019222435A1
(fr)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Procédés de sélection de sujets pour une polythérapie anticancéreuse avec un ph20 soluble conjugué à un polymère
|
|
EP3814327A1
(fr)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
Dérivés d'acide (s)-3-(2-(4-(benzyl)-3-oxopipérazin-1-yl)acétamido)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque et composés apparentés utilisés en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
|
|
SG11202100023XA
(en)
|
2018-07-11 |
2021-01-28 |
Actym Therapeutics Inc |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
|
EP3844276A2
(fr)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Souches bactériennes immunostimulatrices modifiées et utilisations associées
|
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
|
|
CA3117968A1
(fr)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methodes de traitement du cancer avec des inhibiteurs de la farnesyltransferase
|
|
CA3119341A1
(fr)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Methode de traitement d'une tumeur au moyen de l'association de la proteine il-7 et d'un inhibiteur de point de controle immunitaire
|
|
WO2020132071A1
(fr)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Composés interagissant avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladie fibrotique
|
|
WO2020128033A1
(fr)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Métabolisme cellulaire de l'ensemencement d'un réservoir de vih-1 dans des lymphocytes t cd4+
|
|
SG11202106599WA
(en)
|
2018-12-21 |
2021-07-29 |
Kura Oncology Inc |
Therapies for squamous cell carcinomas
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
EP3902913A1
(fr)
|
2018-12-28 |
2021-11-03 |
Catalyst Biosciences, Inc. |
Polypeptides activateurs de plasminogène de type urokinase modifiés et leurs procédés d'utilisation
|
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
|
EP4378958A2
(fr)
|
2019-02-26 |
2024-06-05 |
Inspirna, Inc. |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
|
CA3176660A1
(fr)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Bacteries immunostimulatrices modifiees en vue de coloniser des tumeurs, des cellules immunitaires residant dans une tumeur et le microenvironnement tumoral
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
TW202100506A
(zh)
|
2019-03-07 |
2021-01-01 |
美商柯納特斯製藥公司 |
半胱天冬酶(caspase)抑制劑及其使用方法
|
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
|
WO2020223583A1
(fr)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Méthodes de traitement de la leucémie myéloïde aiguë avec des inhibiteurs de la farnésyltransférase
|
|
JP2022532924A
(ja)
|
2019-05-20 |
2022-07-20 |
ニルバナ サイエンシーズ インク． |
発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
|
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
|
MX2022003166A
(es)
|
2019-09-16 |
2022-06-29 |
Dice Alpha Inc |
Moduladores de il-17a y usos de los mismos.
|
|
EP4058578A2
(fr)
|
2019-11-12 |
2022-09-21 |
Actym Therapeutics, Inc. |
Plateformes d'administration de bactéries immunostimulatrices et leur utilisation pour l'administration de produits thérapeutiques
|
|
AU2021207586A1
(en)
|
2020-01-13 |
2022-07-21 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
|
|
JP2023512657A
(ja)
|
2020-02-05 |
2023-03-28 |
ワシントン・ユニバーシティ |
Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
CA3191433A1
(fr)
|
2020-08-12 |
2022-02-17 |
Actym Therapeutics, Inc. |
Vaccins a base de bacteries immunostimulatrices, agents therapeutiques et plateformes d'administration d'arn
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
WO2022093718A1
(fr)
|
2020-10-26 |
2022-05-05 |
Neoimmunetech, Inc. |
Procédés d'induction de la mobilisation de cellules souches
|
|
WO2022094475A1
(fr)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Utilisation de l'interleukine-7 pour le traitement du coronavirus
|
|
KR20230104175A
(ko)
|
2020-11-05 |
2023-07-07 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질과 뉴클레오타이드 백신의 조합물을 사용한 종양의 치료 방법
|
|
WO2022165000A1
(fr)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Méthodes pour le traitement d'une maladie fibrotique
|
|
WO2022164997A1
(fr)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Méthodes pour le traitement d'une maladie fibrotique
|
|
US20240208968A1
(en)
|
2021-03-10 |
2024-06-27 |
Dice Molecules Sv, Inc. |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
|
WO2022226166A1
(fr)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
|
|
EP4347568A1
(fr)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Hétéroaryl-diamides activateurs d'ire1/xbp1s
|
|
JP2024522213A
(ja)
|
2021-06-14 |
2024-06-11 |
アルジェニクス ビーブイ |
抗ｉｌ－９抗体及びその使用方法
|
|
CA3236150A1
(fr)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Nouveaux agents therapeutiques antiviraux pan-respiratoires a petites molecules ciblant l'hote
|
|
WO2023081923A1
(fr)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Inhibiteurs du récepteur du facteur de croissance dérivé des plaquettes (pdgfr) alpha et leurs utilisations
|
|
WO2023130081A1
(fr)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Procédé de traitement d'une tumeur avec une combinaison d'une protéine il-7 et d'un antagoniste du vegf
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
WO2023198757A1
(fr)
|
2022-04-14 |
2023-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsine pour le traitement d'infections à paramyxoviridae ou orthomyxoviridae
|
|
WO2023201282A1
(fr)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Nouveaux composés gspt1 et procédés d'utilisation des nouveaux composés
|
|
WO2024086852A1
(fr)
|
2022-10-21 |
2024-04-25 |
Diagonal Therapeutics Inc. |
Anticorps agonistes hétéromères dirigés contre récepteur de l'il-18
|
|
WO2024092043A1
(fr)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Composés de pyridine contenant un spirocycle
|
|
US20240174695A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Bicyclic Heteroaryl Compounds
|
|
WO2024092037A1
(fr)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Composés de pyridone contenant un spirocycle
|
|
WO2024102722A1
(fr)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Procédés de traitement d'une tumeur avec un promoteur mgmt non méthylé
|
|
WO2024118801A1
(fr)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Diamides hétéroaryles linéaires comme activateurs d'ire1/xbp1s
|
|
WO2024118810A1
(fr)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Activateurs de ire1/xbp1 diamide de pyrazole cyclique
|